Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Merck & Co. claims new inhibitors of Egl nine homolog 1, 2 and 3

Jan. 19, 2011

Protalix provides update on programs in Gaucher's disease and Fabry's disease

Jan. 19, 2011

Eli Lilly's Byetta is approved in Canada for type 2 diabetes

Jan. 19, 2011

Secondary endpoint met in phase III Corlux trial in Cushing's syndrome

Jan. 19, 2011

Sirona Biochem reports on its sodium/glucose cotransporter 2 inhibitor for type 2 diabetes

Jan. 19, 2011

Vitae Pharma describes new 11-beta-HSD1 inhibitors

Jan. 19, 2011

Lilly and Boehringer Ingelheim enter global diabetes alliance

Jan. 18, 2011

New inhibitors of osteoclast differentiation/stimulation claimed

Jan. 18, 2011

Colesevelam has beneficial effects in patients with type 1 diabetes

Jan. 18, 2011

FDA extends PDUFA date for Gestiva

Jan. 17, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.